

Rybrevant Bispecific Antibody Patent, Sales & Clinical Trials Outlook 2028

<https://marketpublishers.com/r/R1E6F2BC3841EN.html>

Date: October 2021

Pages: 78

Price: US\$ 800.00 (Single User License)

ID: R1E6F2BC3841EN

Abstracts

Please note: extra shipping charges are applied when purchasing Hard Copy License depending on the location.

Rybrevant Bispecific Antibody Patent, Sales & Clinical Trials Outlook 2028 Report
Analysis & Data Highlights:

Rybrevant Patent Insight

Rybrevant Dosage & Price

Rybrevant Sales Forecast 2028: > USD 4 Billion

Rybrevant Role in NSCLC & Other Cancer Therapies

Rybrevant Structure & Pharmacokinetics Properties

Rybrevant Ongoing Clinical Trials: > 5 Clinical Studies

Rybrevant Reimbursement Scenario

The development of bispecific antibodies represents one of the most promising successes in cancer targeted therapy research and development. Bispecific antibodies are dual targeting modalities which can simultaneously combine two epitopes. Their novel dual binding efficacy opens up a wide range of applications application which can be exploited in redirecting T-cells, blocking two different signaling pathways, dual targeting of different disease mediators and delivering payloads to targeted cells. Owing

to their enhance specificity, they are considered as ideal therapeutic molecule for the management of multifactorial cancers.

Recently in 2021, a novel bispecific antibody Rybrevant (Amivantamab) was granted approval by US FDA. Rybrevant is an EGF and MET directed bispecific antibody, developed by Janssen Pharmaceutical which is indicated for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations. Clinical trials have demonstrated that the novel drug has shown enhanced efficacy in comparison to previously approved MET and EGFR inhibitors. As of now, the drug has only gained approval in US. However, it has filed regulatory submissions in other regions including Europe, China, Japan, and other regions.

The approval of drug Rybrevant in early 2021 is thought to revolutionize the paradigm treatment of EGFR mutated non-small cell lung cancer. It is expected that in short span of time, the drug will constitute a major share in the lung cancer therapeutics owing to the single product approval targeting EGFR mutations. It is analyzed that the market will witness high compound annual growth rates to surpass US\$ 4 Billion by 2028. Apart from this, the favorable reimbursement policies including Janssen Care Path will also boost the uptake of drug in the market. Furthermore, the subsequent years will see approval of Rybrevant in different regions, which will further boost the growth of market.

Apart from non-small cell lung cancer, the drug is also being evaluated in other cancers including adenoid cystic carcinoma (ACC), stomach cancer, esophageal cancers, and other solid tumors. In addition to this, investigators are also validating the role of drug in combination with carboplatin, lazertinib, osimertinib, and others which aim to enhance the efficacy of the drug. As per our analysis, the future will see dominance of combinational therapy which is mainly due to its increased efficiency and enhance survival outcomes.

Scientists are constantly exploring the sector of bispecific antibodies. Their multifactorial approach in the management of diseases and their ability to pass through the blood brain barrier is gaining the interest of various researchers. Extensive efforts by research institutions and pharmaceutical sector are boosting the global bispecific antibody market. The major key players in the market are Amgen, Genmab, Eli Lilly, NovImmune, Sanofi, Roche, AstraZeneca, and several others. These have developed robust pipeline of bispecific antibodies which will compete with already approved bispecifics in market.

The transient shift towards sedentary lifestyle and the increase in uptake of smoking,

alcohol and tobacco consumption will led to rise in prevalence of lung cancer which will further propel the market. Moreover, the rates at which conventional therapies are failing possess an unmet need for the novel targeted therapy in the management of cancer. Presently, US contributes to the major share in the market due to several factors such as increasing prevalence of cancer and the expected high sales of Rybrevant will drive the growth of the market during the forecasted period. Moreover, presence of top key players in this region as well as rising awareness and acceptance of novel therapies are also going to fuel the growth of the market in this region. Apart from this, other regions such Europe, Asia-Pacific and Japan are also expanding their markets to secure their position in the global market.

Contents

1. RYBREVANT (AMIVANTAMAB-VMJW): THIRD APPROVED BISPECIFIC ANTIBODY 2021

1.1 Overview

1.2 Approval & Patent Insight

2. RYBREVANT DOSAGE & PRICE ANALYSIS

3. RYBREVANT - STRUCTURE, DESCRIPTION & PHARMACOKINETICS

4. RYBREVANT MECHANISM OF ACTION

4.1 General Mechanism of Bispecific Antibodies

4.2 Rybrevant

5. RYBREVANT ROLE IN NSCLC

6. RYBREVANT ROLE IN OTHER CANCERS

7. RYBREVANT - SUPPLEMENTARY INFORMATION

7.1 Adverse Drug Reactions

7.2 Application in Specific Population

8. RYBREVANT MARKET ANALYSIS

8.1 Current Market Scenario

8.2 Future Market Opportunity

9. RYBREVANT SALES FORECAST

10. RYBREVANT REIMBURSEMENT POLICY

11. RYBREVANT CLINICAL TRIALS INSIGHT

11.1 By Phase

11.2 By Development Status

11.3 By Region

12. ONGOING RESEARCH & DEVELOPMENT

13. COMPANIES DEVELOPING SIMILAR BISPECIFIC ANTIBODIES

13.1 Ablynx

13.2 Adimab

13.3 Affimed Therapeutics

13.4 Amgen

13.5 AstraZeneca (MedImmune)

13.6 Chugai Pharmaceutical

13.7 Eli Lilly

13.8 EMD Serono

13.9 Emergent BioSolutions

13.10 Genentech

13.11 Genmab

13.12 Immunomedics

13.13 Jounce Therapeutics

13.14 MacroGenics

13.15 Merus

13.16 Neovii Biotech

13.17 NovImmune

13.18 OncoMed Pharmaceuticals

13.19 Pieris

13.20 Regeneron Pharmaceuticals

13.21 Roche

13.22 Sanofi

List Of Figures

LIST OF FIGURES

Figure 1-1: Rybrevant – Response Rate (%)

Figure 1-2: Rybrevant – FDA Breakthrough Designation & Approval Year

Figure 2-1: Rybrevant – Price for 7ml Supply & Price per Unit of 50mg/ml Intravenous Solution (US\$), October'2021

Figure 2-2: Rybrevant – Recommended Dose Per Cycle by Body Weight (mg)

Figure 2-3: Rybrevant – Dose Reduction in Patients with Weight Less Than 80Kg (mg)

Figure 2-4: Rybrevant – Dose Reduction in Patients with Weight More Than 80Kg (mg)

Figure 2-5: Rybrevant – Cost of Single Treatment Cycle (US\$), October'2021

Figure 2-6: Rybrevant – Cost of Annual Treatment (US\$), October'2021

Figure 4-1: Bispecific Antibodies – General Mechanism of Action

Figure 4-2: Bispecific Antibodies: Pathways for Induction of Cytotoxicity

Figure 4-3: Rybrevant - Mechanism of Action

Figure 5-1: Global – Newly Diagnosed Cases & Deaths Related to Lung Cancer (Million), 2020

Figure 5-2: Global – Lung Cancer Incidence by Type (%), 2020

Figure 5-3: Impact of Rybrevant over the NSCLC Cells

Figure 6-1: Global – Newly Diagnosed ACC, Stomach & Esophageal Cancer Cases, 2028

Figure 6-2: Impact of Rybrevant on MET & EGFR Mutated Cancers

Figure 7-1: Rybrevant Associated Adverse Events

Figure 8-1: Global – Estimated EGFR Exon 20 Insertion Mutated NSCLC Population for Rybrevant, 2021-2028

Figure 8-2: Global – Rybrevant Market Opportunity by 1% Adaptation Rate in EGFR Exon 20 Insertion Mutated NSCLC (US\$ Million), 2021 - 2028

Figure 8-3: Global – Rybrevant Market Opportunity by 2% Adaptation Rate in EGFR Exon 20 Insertion Mutated NSCLC (US\$ Million), 2021 - 2028

Figure 8-4: Global – Rybrevant Market Opportunity by 3% Adaptation Rate in EGFR Exon 20 Insertion Mutated NSCLC (US\$ Million), 2021 - 2028

Figure 8-5: Global – Rybrevant Market Opportunity by 4% Adaptation Rate in EGFR Exon 20 Insertion Mutated NSCLC (US\$ Million), 2021 - 2028

Figure 8-6: Global – Rybrevant Market Opportunity by 5% Adaptation Rate in EGFR Exon 20 Insertion Mutated NSCLC (US\$ Million), 2021 - 2028

Figure 8-7: Global – Estimated ACC Population for Rybrevant, 2021-2028

Figure 8-8: Global – Rybrevant Market Opportunity by 1% Adaptation Rate in ACC Patients (US\$ Million), 2021 - 2028

Figure 8-9: Global – Rybrevant Market Opportunity by 2% Adaptation Rate in ACC Patients (US\$ Million), 2021 - 2028

Figure 8-10: Global – Rybrevant Market Opportunity by 3% Adaptation Rate in ACC Patients (US\$ Million), 2021 - 2028

Figure 8-11: Global – Rybrevant Market Opportunity by 4% Adaptation Rate in ACC Patients (US\$ Million), 2021 - 2028

Figure 8-12: Global – Rybrevant Market Opportunity by 5% Adaptation Rate in ACC Patients (US\$ Million), 2021 - 2028

Figure 8-13: Global – Rybrevant Market Opportunity by 6% Adaptation Rate in ACC Patients (US\$ Billion), 2021 - 2028

Figure 8-14: Global – Rybrevant Market Opportunity by 7% Adaptation Rate in ACC Patients (US\$ Billion), 2021 - 2028

Figure 8-15: Global – Rybrevant Market Opportunity by 8% Adaptation Rate in ACC Patients (US\$ Billion), 2021 - 2028

Figure 8-16: Global – Rybrevant Market Opportunity by 9% Adaptation Rate in ACC Patients (US\$ Million), 2021 - 2028

Figure 8-17: Global – Rybrevant Market Opportunity by 10% Adaptation Rate in ACC Patients (US\$ Million), 2021 - 2028

Figure 6-1: Global – Newly Diagnosed Stomach & Esophageal Cancer Cases, 2028

Figure 9-1: Global – Rybrevant Sales Forecast (US\$ Million), 2021-2028

Figure 9-2: US – Rybrevant Sales Forecast (US\$ Million), 2021-2028

Figure 9-3: ROW – Rybrevant Sales Forecast (US\$ Million), 2022-2028

Figure 10-1: Global – Rybrevant Maximum Coverage by Medicaid (US\$), 2021

Figure 10-2: Global – Rybrevant Maximum Coverage by Private Insurance Coverage (US\$), 2021

Figure 11-1: Global – Number of Rybrevant Related Clinical Trials by Phase, October'2021

Figure 11-2: Global – Rybrevant Related Clinical Trials by Phase (%), October'2021

Figure 11-3: Global – Number of Rybrevant Related Clinical Trials by Development Status, October'2021

Figure 11-4: Global – Number of Rybrevant Related Clinical Trials by Development Status (%), October'2021

Figure 11-5: Global – Number of Rybrevant Related Clinical Trials by Region, October'2021

Figure 12-1: Rybrevant Phase II Trial – Salivary Gland Cancer Study Initiation & Completion Year

Figure 12-2: Rybrevant Phase II Trial – Gastric & Esophageal Cancer Study Initiation & Completion Year

Figure 12-3: Rybrevant Phase II Combinational Trial – Amivantamab & Lazertinib Study

Initiation & Completion Year

Figure 12-4: Rybrevant Phase III Combinational Trial – Amivantamab, Pemetrexed and Carboplatin Study Initiation & Completion Year

Figure 12-5: Rybrevant Phase I Combinational Trial – Amivantamab, Lazertinib, Carboplatin & Pemetrexed Study Initiation & Completion Year

Figure 13-1: Ablynx - Clinical Pipeline

Figure 13-2: Affimed Therapeutics - Clinical Pipeline

Figure 13-3: Amgen - Clinical Pipeline

Figure 13-4: EMD Serono - Clinical Pipeline

Figure 13-5: Emergent Bioscience - Clinical Pipeline

Figure 13-6: Genmab - Clinical Pipeline

Figure 13-7: Jounce Therapeutics - Clinical Pipeline

Figure 13-8: MacroGenics - Clinical Pipeline

Figure 13-9: Merus - Clinical Pipeline

Figure 13-10: Novimmune - Clinical Pipeline

Figure 13-11: OncoMed - Clinical Pipeline

Figure 13-12: Pieris Pharmaceuticals - Clinical Pipeline

Figure 13-13: Roche - Clinical Pipeline

I would like to order

Product name: Rybrevant Bispecific Antibody Patent, Sales & Clinical Trials Outlook 2028

Product link: <https://marketpublishers.com/r/R1E6F2BC3841EN.html>

Price: US\$ 800.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/R1E6F2BC3841EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970